Transition to a capital light operating model; with lower cost operations Continued focus on the Company's core business of "EasyDNA" and "GeneType" Working capital funded by short term $800,000 secured loan (from lenders including Directors) Active Channel partners in the USA with geneType sales growth EasyDNA sales of $7m and growing The Company intends to fund working capital requirements with (i) a secured loan facility of $800,000; plus (ii) launching an Entitlement Offer. EasyDNA and AffinityDNA proje ...

Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and consumer segments that include senior finance leadership roles with major ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited. More recently, in roles as an executive, interim or non-executive director he has been supporting emerging, technology-driven businesses scale, g ...

Forward Looking Statements MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and ...

Core Viewpoint - WiMi Hologram Cloud Inc. has announced a new blockchain consensus algorithm based on genetic algorithms, aimed at improving computational efficiency and overall performance in consortium blockchain networks [1][4]. Group 1: Blockchain Technology - The genetic algorithm is a stochastic search and optimization technique that enhances the consensus process by selecting the best nodes in a coalition blockchain network [2][3]. - This algorithm improves the efficiency of consensus, block generation, and computation by filtering consensus nodes based on their performance metrics [3][4]. - The optimization of the consensus mechanism is a complex and ongoing process, with expectations for more efficient algorithms to emerge in the future [4]. Group 2: Company Overview - WiMi Hologram Cloud, Inc. is a comprehensive technical solution provider specializing in holographic AR technologies, including automotive HUD software, 3D holographic pulse LiDAR, and holographic communication [5]. - The company focuses on various professional areas, offering services that encompass holographic AR applications, software development, and advertising technologies [5].

CHARLOTTE, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, today announced the introduction of geneType's suite of genetic risk assessment tests to Canada and New Zealand. Dovetailing geneType's recent expansion to the US market under its partnership with health and wellness technology leader Stayhealthy, Inc ("Stayhealthy"), t ...

GeneType is revolutionizing healthcare with its pioneering, non-invasive Multi-Risk Test, designed to uncover hidden risks of common yet serious diseases. This state-of-the-art test identifies individuals at elevated risk for a range of cancers, including breast, ovarian, pancreatic, prostate, colorectal, and melanoma, as well as cardiovascular diseases and metabolic conditions like Type 2 diabetes. Real Impact, Real Lives: About Genetic Technologies Limited Since the geneType Risk Assessment Tests became a ...

CHARLOTTE, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk and improving the health of populations worldwide. Since the geneType Risk Assessment Tests became available, GTG has tested a statistically significant number of people in Australia and the US. These results have revealed a compelling ...

The exclusive event, hosted by RedChip Companies, will feature Simon Morriss, CEO of Genetic Technologies, who will share insight into the Company's portfolio of genomics-based tests targeting health, wellness and serious disease, including the geneType multi-risk test. Scaling existing sales channels - amplifying existing sales channels for enhanced market penetration and share. Aggressive marketing - harnessing our digital initiative to swiftly tap into the burgeoning direct-toconsumer market. Expanding t ...

Core Insights - Genetic Technologies Limited (GTG) has commenced testing operations in the U.S. for its geneType™ genetic risk assessment product series, marking a significant expansion in its service offerings [1][3] - The company has developed a suite of integrated genetic testing tools that assess individual risks for serious diseases, leveraging its pioneering work in polygenic risk scores (PRS) [2][4] - GTG's collaboration with Gene by Gene and Stayhealthy enhances its operational capacity and distribution network in North America, positioning the company for substantial growth [7][9] Company Overview - Genetic Technologies Limited is a leader in genomics-based tests, focusing on health, wellness, and serious diseases through its geneType and EasyDNA brands [4][11] - The company has developed a proprietary risk stratification platform over the past decade, integrating clinical and genetic risk to provide actionable outcomes for healthcare providers and individuals [4][12] - GTG's geneType tests are clinically validated and regulatory approved, with a focus on non-invasive, saliva-based assessments for various diseases [8][12] Strategic Partnerships - The partnership with Gene by Gene, a highly accredited genetic laboratory, allows GTG to process up to 25,000 tests per month, significantly increasing its operational capacity [7] - Stayhealthy's collaboration will broaden the reach of geneType's tests through employee health benefits and online pharmacy channels, targeting a consumer base of up to 1.5 million users [9] - Stayhealthy's extensive database of over 200 million U.S. email addresses positions it well to promote geneType's health risk assessments across North America [9]

SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition. Bipolar disorder is a mental health condition that can cause extreme and unusual shifts in mood, energy, behavior and activity, ranging from highs (mania) to ...